Biological Psychiatry
Volume 61, Issue 5 , Pages 671-678 , 1 March 2007

Noradrenergic Augmentation of Escitalopram Response by Risperidone: Electrophysiologic Studies in the Rat Brain

  • Eliyahu Dremencov

      Affiliations

    • University of Ottawa Institute of Mental Health Research, Ottawa, Canada
    • ,
  • Mostafa El Mansari

      Affiliations

    • University of Ottawa Institute of Mental Health Research, Ottawa, Canada
    • ,
  • Pierre Blier

      Affiliations

    • University of Ottawa Institute of Mental Health Research, Ottawa, Canada
    • Departments of Psychiatry and Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.
    • Corresponding Author InformationAddress reprint requests to Pierre Blier, M.D., Ph.D., University of Ottawa Institute of Mental Health Research, Mood Disorders Research, 1145 Carling Avenue, LG 2043, Ottawa ON K1Z-7K4, Canada

Received 27 March 2006 ,Revised 18 May 2006 ,Accepted 22 May 2006.

References 

  1. Andersson JL, Marcus M, Nomikos GG, Svensson TH. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol. 1994;349:236–243
  2. Blier P. Medication combination and augmentation strategies in the treatment of major depression. In:  Stein DJ,  Kupfer DJ,  Schatzberg AF editor. The American Textbook of Mood Disorders. Washington, DC: American Psychiatric Publishing Inc; 2005;p. 509–524
  3. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96
  4. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl). 1996;124:87–94
  5. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29:252–265
  6. Chaput Y, Lesieur P, de Montigny C. Effects of short-term serotonin depletion on the efficacy of serotonin neurotransmission: Electrophysiological studies in the rat central nervous system. Synapse. 1990;6:328–337
  7. Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mork A, et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology. 2004;29:1782–1789
  8. Dawe GS, Huff KD, Vandergriff JL, Sharp T, O’Neill MJ, Rasmussen K. Olanzapine activates the rat locus coeruleus: In vivo electrophysiology and c-fos immunoreactivity. Biol Psychiatry. 2001;50:510–520
  9. Devoto P, Flore G, Saba P, Fa M, Gessa GL. Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus. BMC Neurosci. 2005;6:31
  10. Dinan TG, Aston-Jones G. Acute haloperidol increases impulse activity of brain noradrenergic neurons. Brain Res. 1984;307:359–362
  11. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain. Neuropsychopharmacology. 2005;30:1269–1277
  12. Florin-Lechner SM, Druhan JP, Aston-Jones G, Valentino RJ. Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res. 1996;742:89–97
  13. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: Burst firing. J Neurosci. 1984;4:2877–2890
  14. Gronier BS, Rasmussen K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neuroscience. 2003;9:196–200
  15. Haddjeri N, de Montigny C, Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. Br J Pharmacol. 1997;120:865–875
  16. Hatanaka K, Yatsugi S, Yamaguchi T. Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur J Pharmacol. 2000;395:31–36
  17. Hertel P, Lindblom N, Nomikos GG, Svensson TH. Receptor-mediated regulation of serotonin output in the rat dorsal raphe nucleus: Effects of risperidone. Psychopharmacology (Berl). 2001;153:307–314
  18. Hertel P, Nomikos GG, Schilstrom B, Arborelius L, Svensson TH. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: Role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology. 1997;17:44–55
  19. Hertel P, Nomikos GG, Svensson TH. The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacology. 1999;38:1175–1184
  20. Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: Dopamine D2 receptor partial agonist. J Med Invest. 2005;52(suppl):284–290
  21. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al. Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. J Clin Psychiatry. 2002;63:826–837
  22. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl). 2006;185:274–281
  23. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988;244:685–693
  24. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: A focus on atypical antipsychotics. Bipolar Disord. 2003;5(suppl 2):36–47
  25. Marek GJ, Martin-Ruiz R, Abo A, Artigas F. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology. 2005;30:2205–2215
  26. Mongeau R, Blier P, de Montigny C. The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments. Brain Res Brain Res Rev. 1997;23:145–195
  27. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology. 2003;45:167–173
  28. Nasif FJ, Cuadra GR, Ramirez OA. Effects of chronic risperidone on central noradrenergic transmission. Eur J Pharmacol. 2000;394:67–73
  29. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005;66(suppl 8):13–21
  30. Nilsson LK, Schwieler L, Engberg G, Linderholm KR, Erhardt S. Activation of noradrenergic locus coeruleus neurons by clozapine and haloperidol: Involvement of glutamatergic mechanisms. Int J Neuropsychopharmacol. 2005;8:329–339
  31. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005;66:1326–1330
  32. Piercey MF, Tang AH, Lahti RA, VonVoigtlander PF, Schreur PJ, McCall RB, et al. Pharmacology of a mixed 5-hydroxytryptamine1A/dopamine agonist. J Pharmacol Exp Ther. 1994;268:1304–1310
  33. Pineyro G, Blier P. Autoregulation of serotonin neurons: Role in antidepressant drug action. Pharmacol Rev. 1999;51:533–591
  34. Reader TA, Briere R, Grondin L, Ferron A. Effects of p-chlorophenylalanine on cortical monoamines and on the activity of noradrenergic neurons. Neurochem Res. 1986;11:1025–1035
  35. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57–73
  36. Seager MA, Barth VN, Phebus LA, Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: Implications for bipolar disorder. Psychopharmacology (Berl). 2005;181:126–133
  37. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65:1715–1719
  38. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry. 2005;66:1216–1220
  39. Szabo ST, Blier P. Response of the norepinephrine system to antidepressant drugs. CNS Spectr. 2001;6:679–684
  40. Szabo ST, Blier P. Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: A microiontophoretic study in the rat locus coeruleus. Synapse. 2001;42:203–212
  41. Szabo ST, Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther. 2002;302:983–991
  42. Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2000;3:1–11
  43. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–1088
  44. Tung CS, Ugedo L, Grenhoff J, Engberg G, Svensson TH. Peripheral induction of burst firing in locus coeruleus neurons by nicotine mediated via excitatory amino acids. Synapse. 1989;4:313–318
  45. Uzun S, Kozumplik O, Mimica N, Folnegovic-Smalc V. Aripiprazole: An overview of a novel antipsychotic. Psychiatr Danub. 2005;17:67–75
  46. Yang TT, Wang SJ. Effects of haloperidol and clozapine on glutamate release from nerve terminals isolated from rat prefrontal cortex. Synapse. 2005;56:12–20
  47. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000;23:250–262

PII: S0006-3223(06)00659-7

doi: 10.1016/j.biopsych.2006.05.015

Biological Psychiatry
Volume 61, Issue 5 , Pages 671-678 , 1 March 2007

Article Tools

* Image Usage & Resolution